FDA Identifies Potential Problem Drugs

Posted on Sep 10, 2008
Last year, Congress ordered the Food & Drug Administration (FDA) to post quarterly listings of medications under investigation.  The FDA released its first quarterly listing this month, identifying the following drugs as under investigation:

1.    R-Gene 10, a growth hormone, pediatric overdose due to labeling/packaging confusion.
2.    Suprane, an anesthetic, cardiac arrest.
3.    Cymbalta, for depression and other conditions, urinary retention.
4.    Intelence, an HIV medication, bleeding into joints.
5.    Carac and Kuric, creams for skin conditions and fungal infections, name confusion.
6.    Heparin, a blood-thinner, serious allergic reactions.
7.    Extraneal, used in kidney dialysis, low blood sugars.
8.    Humilin R, for diabetes, dosing confusion.
9.    Stromectol and Warfarin, an anti-parasite drug and a blood thinner, drug interaction.
10.  Tykerb, for advanced breast cancer, liver damage.
11.  Revlimid, for multiple myeloma, severe skin blistering and bleeding.
12.  Tysabri, for multiple sclerosis, skin melanomas.
13.  Nitrostat, for angina, overdose due to labeling confusion.
14.  Sandostatin LAR, for abnormal bone growth, bowel obstruction.
15.  Oxycontin, a pain killer, drug misuse, abuse and overdose.
16.  Definity, used in cardiac imaging, cardiopulmonary reactions.
17.  Dilantin injection, for epileptic seizures, serious skin reaction.
18.  Seroquel, for bipolar disorder, overdose due to sample pack labeling confusion.
19.  Tyzeka, for chronic hepatitis B, nerve damage.
20.  Tumor Necrosis Factor (TNF) Blockers, for juvenile arthritis, cancers in children and young adults.

Read More About FDA Identifies Potential Problem Drugs...

Michael J. Shevlin
Connect with me
Specializing in medical malpractice and serious personal injury cases since 1994.